A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%. The combination of thalidomide with dexamethasone (Thal/Dex) is expected to improve responses, but it is unknown if the combination increases the rate of adverse events. Here, we conducted a systematic r...

Descripción completa

Detalles Bibliográficos
Autores principales: von Lilienfeld-Toal, Marie, Hahn-Ast, Corinna, Furkert, Kerstin, Hoffmann, Florian, Naumann, Ralph, Bargou, Ralf, Cook, Gordon, Glasmacher, Axel
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613233/
https://www.ncbi.nlm.nih.gov/pubmed/18637031
http://dx.doi.org/10.1111/j.1600-0609.2008.01121.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613233/
https://www.ncbi.nlm.nih.gov/pubmed/18637031
http://dx.doi.org/10.1111/j.1600-0609.2008.01121.x

Ejemplares similares